KRTAP10-5: A Potential Drug Target and Biomarker (G386680)

Target Name: KRTAP10-5

NCBI ID: G386680

KRTAP10-5

KRTAP10-5: A Potential Drug Target and Biomarker

KRTAP10-5, also known as KRTAP18.1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is Kallikrein-related peptidase 10-5, and it is a member of the serine proteases family 10. KRTAP10-5 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The protein encoded by the KRTAP10-5 gene is a 16.1 kDa serine protease that is involved in the degradation of various extracellular matrix (ECM) components, including collagen, elastin, and hyaluronic acid. ECM components are important components of the extracellular matrix that provide support and structure to various tissues and organs, and they are often involved in various physiological processes, including cell signaling, tissue repair, and inflammation.

KRTAP10-5 has been shown to play a crucial role in the regulation of ECM degradation and the balance of ECM components. It is involved in the degradation of ECM components that are involved in cancer progression, including ECM-derived growth factors (EMFs), which are known to promote the growth and survival of cancer cells. In addition, KRTAP10-5 is involved in the degradation of ECM components that are involved in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

KRTAP10-5 has also been shown to be involved in the regulation of immune responses and inflammation. It is involved in the degradation of ECM components that are involved in the development and maintenance of immune tolerance, including ECM-derived MHC class I molecules. In addition, KRTAP10-5 is involved in the regulation of inflammation, including the production of pro-inflammatory cytokines.

The potential drug targets for KRTAP10-5 include the inhibition of its activity as a serine protease, as well as the targeting of KRTAP10-5-mediated signaling pathways. There are several potential drug candidates that have been shown to interact with KRTAP10-5, including small molecules, peptides, and antibodies. These drugs have the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential drug targets, KRTAP10-5 is also a potential biomarker for several diseases. The loss of KRTAP10-5 has been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, KRTAP10-5 has been shown to be involved in the regulation of cellular processes that are involved in disease progression, including cell signaling, apoptosis, and inflammation.

Overall, KRTAP10-5 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in the regulation of ECM degradation and immune responses, as well as its potential as a drug and biomarker.

Protein Name: Keratin Associated Protein 10-5

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP10-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP10-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets